Bluejay Diagnostics Stock Surges 115% on Expanded Partnership with SanyoSeiko
Bluejay Diagnostics (BJDX) shares soared 115% Thursday after announcing an expanded collaboration with Japan's SanyoSeiko to accelerate commercialization of its Symphony diagnostic platform. The medical device manufacturer will now provide end-to-end support, including manufacturing redevelopment, supply chain management, and contract production for analyzers and cartridges.
CEO Neil Dey framed the partnership as a strategic milestone, emphasizing strengthened supply chain resilience and production capacity ahead of broader clinical trials. The Symphony system aims to deliver rapid biomarker test results, positioning Bluejay in the growing point-of-care diagnostics market.